# Propep Surgical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/propep-surgical

- Industry: Medical Devices & Equipment
- Headquarters: Austin, US
- Website: www.propepsurgical.com
- Total disclosed funding: $1.3M
- Latest round: Series A (Apr 22, 2013)
- Investors on record: 1

## About

Propep Surgical specializes in advanced nerve monitoring technology for robotic and laparoscopic prostate surgeries, enhancing surgical precision and patient outcomes.Propep Surgical was founded in 2010 in Austin, US, focusing on nerve monitoring solutions. The firm raised USD 1.25 mn in Series A funding in April 2013 from Stella Maris Partners. Founders Jann Rasmussen and Jon Schiff have experience in the medical technology sector, contributing to the company's innovative approach. The firm has completed one deal to date, with its headquarters located in Austin, Texas.ProPep Surgical develops the ProPep® Nerve Monitoring System, the first FDA-cleared real-time nerve monitoring solution for robotic and laparoscopic prostate surgeries. This technology assists surgeons in identifying critical somatic nerves, thereby reducing the risk of postoperative complications like sexual dysfunction and urinary incontinence. The firm's products serve urologists and surgical professionals in North America and select European markets, specifically targeting patients undergoing prostatectomy procedures.ProPep Surgical generates revenue from sales of its ProPep® Nerve Monitoring System to healthcare facilities and surgical practices, typically involving direct sales to hospitals and surgical centers. The B2B model fosters partnerships with medical institutions and includes revenue from one-time equipment purchases and ongoing support and training services for medical staff.Propep Surgical plans to leverage recent funding from the USD 1.25 mn Series A financing to enhance its product offerings and expand into new markets. The company is focusing on developing additional products for nerve monitoring and targeting expansion into more European regions by the end of 2024. This strategy aims to increase market presence and improve surgical outcomes in prostate cancer treatments.

## Funding rounds

- Series A, Apr 22, 2013, $1.3M — Stella Maris Partners

## Investors

- Stella Maris Partners (https://capitalatlas.ai/funds/stella-maris-partners) — Series A